(Q53780736)

19 May 2018

review article

1 reference

title

Clinical pharmacology of camptothecins. (English)

1 reference

19 May 2018

1 reference

2

Ratain MJ

1 reference

19 May 2018

author name string

Iyer L

series ordinal

1

1 reference

19 May 2018

publication date

1 January 1998

1 reference

19 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

19 May 2018

volume

42 Suppl

1 reference

19 May 2018

page(s)

S31-43

1 reference

19 May 2018

https://scigraph.springernature.com/pub.10.1007/s002800051077

exact match

0 references

cites work

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Clinical studies of topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Clinical pharmacology and pharmacodynamics of irinotecan. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Topoisomerase I inhibitors: topotecan and irenotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Current perspectives on camptothecins in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Clinical pharmacokinetics of topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Pharmacokinetics of camptothecins administered orally

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Topoisomerase I and II activity in human breast, cervix, lung and colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

9-Aminocamptothecin and beyond. Preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

The current status of irinotecan (CPT-11) in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Camptothecin analogues: studies from the Johns Hopkins Oncology Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Preclinical and phase I trials of topoisomerase I inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Topoisomerase-I inhibitors in the management of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

FDA approve bark-derived drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Intrathecal administration of topotecan in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Trials of 9-amino-20(S)-camptothecin in Boston

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Mechanism of action of camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacologic study of topotecan in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I study of topotecan for pediatric patients with malignant solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacokinetic trial of weekly CPT-11

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Clinical pharmacology of 9-aminocamptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051077

21 January 2018

Identifiers

DOI

10.1007/S002800051077

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kib2mc7cafgztl4etoxyqgakfq

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_kib2mc7cafgztl4etoxyqgakfq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kib2mc7cafgztl4etoxyqgakfq

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/kib2mc7cafgztl4etoxyqgakfq

1 reference